Can the ESPRIT results end the antiplatelet battle between neurologists and cardiologists?

摘要

The combination of extended-release dipy-ridamole and aspirin is an effective therapy for secondary stroke prevention.1 Some cardiologists avoid this combination, however, because of concern that dipyridamole might increase the risk of cardiac events in patients with coronary artery disease (CAD). A dilemma can, therefore, arise when a patient with stable CAD suffers an ischemic stroke or transient ischemic attack (TIA)-the combination of dipyridamole and aspirin is prescribed for secondary stroke prevention by a neurologist and, subsequently, the patient's cardiologist recommends that this therapy be discontinued.